AAD: Upadacitinib Safe, Effective for Nonsegmental Vitiligo

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 6, 2026.

via HealthDay

MONDAY, April 6, 2026 -- Treatment with upadacitinib is safe and effective for adults and adolescents with nonsegmental vitiligo (NSV), according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Thierry Passeron, M.D., Ph.D., from the Université Côte d'Azur in Nice, France, and colleagues evaluated the safety and efficacy of upadacitinib (15 mg), a selective once-daily Janus kinase 1 inhibitor, in adults and adolescents with NSV in two identical phase 3 studies (Viti-Up-1 and Viti-Up-2). For the studies, 308 and 306 patients across skin types were randomly assigned to upadacitinib or placebo, respectively.

The researchers found that a greater proportion of patients receiving upadacitinib achieved ≥50 percent improvement in total repigmentation (Total Vitiligo Area Scoring Index [T-VASI] ≥50 percent: upadacitinib, 19.4 percent in Viti-Up-1 and 21.5 percent in Viti-Up-2 compared with 5.9 percent for placebo in both studies) at week 48. Patients receiving upadacitinib also achieved ≥75 percent facial repigmentation (F-VASI: upadacitinib, 25.2 percent in Viti-Up-1 and 23.4 percent in Viti-Up-2 compared with 5.9 and 6.9 percent, respectively, for placebo) at week 48. Similarly, higher proportions of patients treated with upadacitinib achieved ranked secondary end points of F-VASI50 at week 48, F-VASI75 at week 24, and F-VASI90 at week 48. No new safety signals emerged.

"Results indicate that upadacitinib treatment provides clinically meaningful repigmentation for adults and adolescents with NSV," the authors write.

The Viti-Up studies were sponsored by AbbVie, the manufacturer of upadacitinib.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-07 01:53

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords